NCT00750698Phase 2Terminated

A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib

Study sponsor: Syndax Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2010-05Actual
Enrollment · participants8Actual
Source updated2023-07-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview